Aspirin as the Antiplatelet of First Choice in Atherosclerosis: Dual Pharmacodynamic Mechanism and Cancer Screening Role
Abstract
Despite recent criticism and emerging P2Y12 inhibitors, aspirin maintains its position as the cornerstone antiplatelet agent in atherosclerotic cardiovascular disease (ASCVD) prevention. This article argues that aspirin's advantages extend beyond conventional antiplatelet effects through three mechanisms: (1) dual pharmacodynamic action—antiplatelet + antiinflammatory targeting atherosclerosis as a metabolic-inflammatory disease, (2) established efficacy in both primary and secondary prevention per current ACC/AHA/ESC guidelines, and (3) unexpected screening role in early cancer diagnosis through aspirin-triggered bleeding unmasking silent malignancies. These mechanisms collectively support aspirin as the antiplatelet of first choice in ASCVD management. Contemporary specialists should critically reassess modern attacks on aspirin before abandoning this cornerstone therapy, as in reality aspirin can occur as the better choice in both primary and secondary prevention applications.
Introduction: The Current Debate
Recent scientific literature has questioned aspirin's role, particularly in primary prevention, citing bleeding risks that may outweigh modest cardiovascular benefits. The 2026 ACC Antiplatelet Guidance synthesizes major guidelines but maintains aspirin as default for chronic coronary syndromes and remote revascularization. P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) show promising results in de-escalation strategies, with some studies demonstrating superiority over aspirin.[pubmed.ncbi.nlm.nih]
However, this criticism overlooks three critical mechanisms that uniquely position aspirin for ASCVD treatment:
Atherosclerosis is fundamentally a metabolic-inflammatory disease—aspirin's dual antiplatelet+antiinflammatory action addresses this pathophysiology
Current guidelines still recommend aspirin for secondary prevention and selectively for primary prevention in high-risk patients
Aspirin-triggered bleeding serves as early cancer detection signal, providing additional health benefits beyond cardiovascular protection
This article synthesizes evidence supporting these mechanisms and argues for aspirin's primacy in ASCVD management, while calling specialists to more carefully evaluate modern attacks on aspirin before dismissing this cornerstone therapy.
Part 1: Atherosclerosis as Metabolic-Inflammatory Disease and Aspirin's Dual Pharmacodynamic Action
1.1 The Pathophysiological Basis
Atherosclerosis is not merely a lipid-deposition disorder but a chronic inflammatory condition mediated by transcription factors including NF-κB, PPARs, and AP-2α. Vascular injury in acute coronary syndromes involves complex cross-talk between inflammatory mediators, platelets, and thrombosis, where platelet-thrombogen interaction is central.[pmc.ncbi.nlm.nih]
1.2 Aspirin's Antiplatelet Mechanism
At cardiovascular doses (75-325 mg/day), aspirin irreversibly inhibits COX-1, blocking thromboxane A2 production and preventing platelet activation. This mechanism is well-established and shared with other antiplatelet agents.[jamanetwork]
1.3 Aspirin's Antiinflammatory Mechanism—The Critical Difference
Unlike other antiplatelet agents, aspirin acetylates COX-2, generating novel antiinflammatory mediators:
At antiplatelet doses (100-300 mg/day), aspirin demonstrates significant antiinflammatory effects that may contribute to cardiovascular protection beyond platelet inhibition. The 2026 systematic review confirms aspirin's potential effects on transcription factors related to inflammation in atherosclerosis.[pubmed.ncbi.nlm.nih]
1.4 Why This Dual Mechanism Matters
P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) lack antiinflammatory properties. They inhibit platelet activation through P2Y12 receptor blockade but do not acetylate COX-2 or generate lipoxins.
This creates a fundamental advantage for aspirin in treating atherosclerosis as a metabolic-inflammatory disease:
Antiplatelet effect: Prevents thrombotic events (shared with P2Y12 inhibitors)
Antiinflammatory effect: Targets underlying disease pathophysiology (unique to aspirin)
Combined benefit: Addresses both thrombotic complications AND inflammatory progression
Current trials have not proven clinical benefit from antiinflammatory-based strategies despite documented biological differences, suggesting this advantage remains underexploited rather than absent.
Part 2: Current Guidelines Still Support Aspirin as First Choice
2.1 Secondary Prevention—Unquestioned Role
Current guidelines universally recommend aspirin for secondary prevention:
Key evidence: 30 years of Antiplatelet Trialists' Collaboration data (145 randomized trials) supports medium-dose aspirin (75-325 mg/day) for preventing death, MI, and stroke.[acc]
2.2 Primary Prevention—Selective but Established Use
Current guidelines maintain aspirin for primary prevention in specific high-risk populations:
The USPSTF concludes with moderate certainty that aspirin for primary prevention has a "small net benefit" vs. bleeding risk in 40-50 year olds.[acc]
2.3 Why Guidelines Maintain Aspirin's Position
Current cardiovascular treatment guidelines do not recommend substituting P2Y12 inhibitors for aspirin because:
Unconvincing superiority: No regulatory superiority claim for P2Y12 inhibitors vs. low-dose aspirin[acc]
Established safety: Large body of evidence for efficacy and safety of low-dose aspirin as antithrombotic agent[acc]
Underutilization problem: Insufficient aspirin use for secondary prevention, particularly in low-income countries[acc]
Compliance critical: Inadequate aspirin compliance increases cardiovascular event risk[acc]
The 2026 ACC statement acknowledges harmony between American and European guidelines on 12-month DAPT default post-ACS and aspirin for medically treated chronic coronary syndromes.
Part 3: Aspirin as Cancer Screening Tool—Early Detection Through Bleeding
3.1 The Danish (Scandinavian) Study Discovery
A 2026 Danish study of 50,771 aspirin initiators (2005-2023) revealed a counterintuitive finding: aspirin-triggered bleeding unmasks silent bladder cancer.[medicalxpress]
3.2 Mechanism of Cancer Detection
Aspirin's antiplatelet effect provides unexpected screening benefit:
Silent tumor exists → causes minor bleeding (asymptomatic)
Aspirin taken → blocks platelet clots → worsens bleeding
Visible bleeding occurs → patient/clinician alerted
Cystoscopy performed → asymptomatic tumor detected
Earlier intervention → less invasive cancer stage
Lead author Malene Söth Hansen (Aarhus University): "We are very encouraged by these results. In the clinical setting, they underline the importance of acting on suspicious bladder cancer symptoms among aspirin initiators".[medicalxpress]
3.3 Additional Cancer Prevention Evidence
Long-term aspirin use demonstrates chemoprotective effects beyond detection:
3.4 Why This Matters for ASCVD Treatment
Aspirin's cancer screening role provides additional positive results beyond cardiovascular protection:
Detection benefit: Bleeding on aspirin = early warning → earlier diagnosis → less invasive cancer[medicalxpress]
Prevention benefit: Long-term aspirin reduces cancer incidence[pmc.ncbi.nlm.nih]
Survival benefit: Aspirin improves cancer survival outcomes[ecancer]
Misleading trial data interpretation: Short-term trials may show "higher cancer incidence" in aspirin groups because aspirin uncovers existing cancer rather than causes it[medicalxpress]
This represents a third mechanism of benefit uniquely provided by aspirin: antiplatelet + antiinflammatory + cancer chemoprevention/detection.
Part 4: Reconciling the Bleeding Risk Debate
4.1 The Bleeding Controversy
Recent meta-analyses report aspirin increases bleeding risk in primary prevention:
58% increased major GI bleeding (OR 1.58, 95% CI 1.29-1.95)[acpjournals]
27% increased hemorrhagic stroke (OR 1.27, 95% CI 0.96-1.68)[acpjournals]
1.39 excess major bleeding events per 1,000 person-years[acpjournals]
In primary prevention, bleeding risk is "unopposed" while cardiovascular benefit is modest.[pubmed.ncbi.nlm.nih]
4.2 Reinterpretation: Bleeding as Early Detection Signal
The Danish study suggests bleeding on aspirin may not be purely harmful:
4.3 Risk Stratification Approach
Current guidelines use bleeding risk stratification to balance benefits:
Aspirin appropriate when:
Secondary prevention (established ASCVD)
Primary prevention + 40-70 years + high ASCVD risk + no bleeding risk
Willing to take daily aspirin + no increased bleeding risk[acc]
Aspirin inappropriate when:
Age >70 years
Increased bleeding risk (any age)
Low ASCVD risk + primary prevention[pmc.ncbi.nlm.nih]
This approach maintains aspirin's role while acknowledging bleeding risk.
Part 5: Responding to ACC 2026 Guidance Criticism of Aspirin
5.1 What the ACC Statement Actually Says
The ACC Antiplatelet Guidance (2026) synthesizes major guidelines and maintains:
Aspirin remains standard for chronic coronary syndromes/remote revascularization
12-month DAPT default post-ACS aligns with ACC/AHA + ESC
Bleeding risk algorithms stratify patients for de-escalation to SAPT within weeks-months
Shorter DAPT + ticagrelor monotherapy increasingly supported
The statement explicitly acknowledges harmony between American and European guidelines on aspirin for medically treated chronic coronary syndromes.
5.2 What the ACC Statement Doesn't Address
The ACC guidance focuses on antiplatelet efficacy and bleeding risk but overlooks:
Antiinflammatory mechanism: No discussion of aspirin's COX-2 acetylation or lipoxin generation[pmc.ncbi.nlm.nih]
Metabolic-inflammatory disease targeting: No recognition that aspirin addresses atherosclerosis pathophysiology beyond thrombosis
Cancer detection benefit: Bleeding discussed purely as harm, not as early cancer warning
Chemoprotective effects: Cancer prevention not considered in benefit-risk assessment
5.3 Why This Matters for Clinical Decision-Making
The ACC statement's narrow focus on antiplatelet effects and bleeding risk may underestimate aspirin's true benefit:
Traditional benefit: Antiplatelet effect prevents thrombosis
Hidden benefit: Antiinflammatory effect targets disease progression
Unexpected benefit: Bleeding unmasks silent cancer → earlier diagnosis
This creates a systematic bias favoring P2Y12 inhibitors in de-escalation strategies when their actual superiority remains unproven.[acc]
Part 6: The Three-Pronged Advantage of Aspirin
6.1 Summary of Mechanisms
6.2 Why P2Y12 Inhibitors Cannot Replace Aspirin
Despite encouraging de-escalation results, P2Y12 inhibitors lack critical advantages:
No antiinflammatory effect: Do not acetylate COX-2 or generate lipoxins[pubmed.ncbi.nlm.nih]
No cancer detection benefit: Bleeding not associated with early cancer detection[medicalxpress]
Unproven superiority: No regulatory claim for superiority vs. aspirin[acc]
Underutilization of aspirin: Global secondary prevention aspirin use remains insufficient[acc]
The 2026 ACC statement acknowledges ESC preference for prasugrel over ticagrelor post-PCI but notes no analogous ACC/AHA recommendation, indicating guideline divergence rather than consensus.
Conclusions and Recommendations
7.1 Aspirin Maintains First-Choice Position
Three mechanisms support aspirin as antiplatelet of first choice in ASCVD:
Dual pharmacodynamic action: Antiplatelet + antiinflammatory targeting atherosclerosis as metabolic-inflammatory disease
Guideline-supported efficacy: Current ACC/AHA/ESC guidelines maintain aspirin for secondary prevention and selective primary prevention
Cancer screening benefit: Aspirin-triggered bleeding unmasks silent malignancies, providing early detection and improved outcomes
7.2 Clinical Recommendations
For Secondary Prevention:
Maintain aspirin as cornerstone therapy (75-100 mg/day)
Do not substitute P2Y12 inhibitors without compelling evidence
Address underutilization in low-income countries
For Primary Prevention:
Use in high-risk patients (40-70 years, ≥10% 10-year CVD risk, no bleeding risk)
Avoid in >70 years or increased bleeding risk
Consider cancer screening benefit in risk-benefit discussion
For Acute Coronary Syndromes:
Follow 12-month DAPT default per ACC/AHA guidelines
Consider de-escalation to SAPT when bleeding risk stratified
Recognize aspirin's antiinflammatory benefit during ACS
7.3 Research Directions
Future studies should:
Test antiinflammatory-based aspirin strategies vs. P2Y12 monotherapy
Quantify cancer detection benefit in cardiovascular trials
Reassess bleeding risk interpretation (detection signal vs. harm)
Develop personalized aspirin dosing based on inflammatory markers
7.4 Critical Call to Specialists
The style and motive of this article is to attract specialists to more carefully estimate modern attacks on aspirin.Recent scientific media criticism and emerging P2Y12 inhibitors have created a narrative questioning aspirin's role, particularly in primary prevention. However, this formation may be premature and incomplete. In reality, aspirin can occur as the better choice in both primary and secondary prevention applications due to its unique three-pronged advantage: dual antiplatelet+antiinflammatory pharmacodynamic mechanism, guideline-supported efficacy, and unexpected cancer screening benefit.
Specialists should critically reassess:
Are modern attacks on aspirin justified by complete evidence? Recent criticism focuses on bleeding risk but overlooks antiinflammatory benefits and cancer detection role
Is P2Y12 inhibitor superiority proven? No regulatory claim exists for superiority vs. aspirin; current guidelines maintain aspirin's position
Are we underestimating aspirin's true benefit? Bleeding may represent early cancer detection rather than purely harmful event
What is the pathophysiological rationale? Atherosclerosis is metabolic-inflammatory disease—does aspirin's dual mechanism better address this than P2Y12 inhibitors alone?
The verdict may differ when all mechanisms are considered. Aspirin's primacy in ASCVD management deserves continued support, not dismissal based on incomplete benefit-risk assessment.
7.5 Final Statement
Despite recent criticism, aspirin remains the antiplatelet of first choice in atherosclerotic cardiovascular disease. Its dual antiplatelet+antiinflammatory mechanism uniquely addresses atherosclerosis as a metabolic-inflammatory disease, current guidelines maintain its position in secondary and selective primary prevention, and its unexpected cancer screening role provides additional health benefits. P2Y12 inhibitors show promise in de-escalation strategies but lack proven superiority and cannot replicate aspirin's three-pronged advantage.
Aspirin as the Antiplatelet of First Choice in Atherosclerosis: Dual Pharmacodynamic Mechanism and Cancer Screening Role
Abstract
Despite recent criticism and emerging P2Y12 inhibitors, aspirin maintains its position as the cornerstone antiplatelet agent in atherosclerotic cardiovascular disease (ASCVD) prevention. This article argues that aspirin's advantages extend beyond conventional antiplatelet effects through three mechanisms: (1) dual pharmacodynamic action—antiplatelet + antiinflammatory targeting atherosclerosis as a metabolic-inflammatory disease, (2) established efficacy in both primary and secondary prevention per current ACC/AHA/ESC guidelines, and (3) unexpected screening role in early cancer diagnosis through aspirin-triggered bleeding unmasking silent malignancies. These mechanisms collectively support aspirin as the antiplatelet of first choice in ASCVD management. Contemporary specialists should critically reassess modern attacks on aspirin before abandoning this cornerstone therapy, as in reality aspirin can occur as the better choice in both primary and secondary prevention applications.
Introduction: The Current Debate
Recent scientific literature has questioned aspirin's role, particularly in primary prevention, citing bleeding risks that may outweigh modest cardiovascular benefits. The 2026 ACC Antiplatelet Guidance synthesizes major guidelines but maintains aspirin as default for chronic coronary syndromes and remote revascularization. P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) show promising results in de-escalation strategies, with some studies demonstrating superiority over aspirin.[pubmed.ncbi.nlm.nih]
However, this criticism overlooks three critical mechanisms that uniquely position aspirin for ASCVD treatment:
Atherosclerosis is fundamentally a metabolic-inflammatory disease—aspirin's dual antiplatelet+antiinflammatory action addresses this pathophysiology
Current guidelines still recommend aspirin for secondary prevention and selectively for primary prevention in high-risk patients
Aspirin-triggered bleeding serves as early cancer detection signal, providing additional health benefits beyond cardiovascular protection
This article synthesizes evidence supporting these mechanisms and argues for aspirin's primacy in ASCVD management, while calling specialists to more carefully evaluate modern attacks on aspirin before dismissing this cornerstone therapy.
Part 1: Atherosclerosis as Metabolic-Inflammatory Disease and Aspirin's Dual Pharmacodynamic Action
1.1 The Pathophysiological Basis
Atherosclerosis is not merely a lipid-deposition disorder but a chronic inflammatory condition mediated by transcription factors including NF-κB, PPARs, and AP-2α. Vascular injury in acute coronary syndromes involves complex cross-talk between inflammatory mediators, platelets, and thrombosis, where platelet-thrombogen interaction is central.[pmc.ncbi.nlm.nih]
1.2 Aspirin's Antiplatelet Mechanism
At cardiovascular doses (75-325 mg/day), aspirin irreversibly inhibits COX-1, blocking thromboxane A2 production and preventing platelet activation. This mechanism is well-established and shared with other antiplatelet agents.[jamanetwork]
1.3 Aspirin's Antiinflammatory Mechanism—The Critical Difference
Unlike other antiplatelet agents, aspirin acetylates COX-2, generating novel antiinflammatory mediators:
At antiplatelet doses (100-300 mg/day), aspirin demonstrates significant antiinflammatory effects that may contribute to cardiovascular protection beyond platelet inhibition. The 2026 systematic review confirms aspirin's potential effects on transcription factors related to inflammation in atherosclerosis.[pubmed.ncbi.nlm.nih]
1.4 Why This Dual Mechanism Matters
P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) lack antiinflammatory properties. They inhibit platelet activation through P2Y12 receptor blockade but do not acetylate COX-2 or generate lipoxins.
This creates a fundamental advantage for aspirin in treating atherosclerosis as a metabolic-inflammatory disease:
Antiplatelet effect: Prevents thrombotic events (shared with P2Y12 inhibitors)
Antiinflammatory effect: Targets underlying disease pathophysiology (unique to aspirin)
Combined benefit: Addresses both thrombotic complications AND inflammatory progression
Current trials have not proven clinical benefit from antiinflammatory-based strategies despite documented biological differences, suggesting this advantage remains underexploited rather than absent.
Part 2: Current Guidelines Still Support Aspirin as First Choice
2.1 Secondary Prevention—Unquestioned Role
Current guidelines universally recommend aspirin for secondary prevention:
Key evidence: 30 years of Antiplatelet Trialists' Collaboration data (145 randomized trials) supports medium-dose aspirin (75-325 mg/day) for preventing death, MI, and stroke.[acc]
2.2 Primary Prevention—Selective but Established Use
Current guidelines maintain aspirin for primary prevention in specific high-risk populations:
The USPSTF concludes with moderate certainty that aspirin for primary prevention has a "small net benefit" vs. bleeding risk in 40-50 year olds.[acc]
2.3 Why Guidelines Maintain Aspirin's Position
Current cardiovascular treatment guidelines do not recommend substituting P2Y12 inhibitors for aspirin because:
Unconvincing superiority: No regulatory superiority claim for P2Y12 inhibitors vs. low-dose aspirin[acc]
Established safety: Large body of evidence for efficacy and safety of low-dose aspirin as antithrombotic agent[acc]
Underutilization problem: Insufficient aspirin use for secondary prevention, particularly in low-income countries[acc]
Compliance critical: Inadequate aspirin compliance increases cardiovascular event risk[acc]
The 2026 ACC statement acknowledges harmony between American and European guidelines on 12-month DAPT default post-ACS and aspirin for medically treated chronic coronary syndromes.
Part 3: Aspirin as Cancer Screening Tool—Early Detection Through Bleeding
3.1 The Danish (Scandinavian) Study Discovery
A 2026 Danish study of 50,771 aspirin initiators (2005-2023) revealed a counterintuitive finding: aspirin-triggered bleeding unmasks silent bladder cancer.[medicalxpress]
3.2 Mechanism of Cancer Detection
Aspirin's antiplatelet effect provides unexpected screening benefit:
Silent tumor exists → causes minor bleeding (asymptomatic)
Aspirin taken → blocks platelet clots → worsens bleeding
Visible bleeding occurs → patient/clinician alerted
Cystoscopy performed → asymptomatic tumor detected
Earlier intervention → less invasive cancer stage
Lead author Malene Söth Hansen (Aarhus University): "We are very encouraged by these results. In the clinical setting, they underline the importance of acting on suspicious bladder cancer symptoms among aspirin initiators".[medicalxpress]
3.3 Additional Cancer Prevention Evidence
Long-term aspirin use demonstrates chemoprotective effects beyond detection:
3.4 Why This Matters for ASCVD Treatment
Aspirin's cancer screening role provides additional positive results beyond cardiovascular protection:
Detection benefit: Bleeding on aspirin = early warning → earlier diagnosis → less invasive cancer[medicalxpress]
Prevention benefit: Long-term aspirin reduces cancer incidence[pmc.ncbi.nlm.nih]
Survival benefit: Aspirin improves cancer survival outcomes[ecancer]
Misleading trial data interpretation: Short-term trials may show "higher cancer incidence" in aspirin groups because aspirin uncovers existing cancer rather than causes it[medicalxpress]
This represents a third mechanism of benefit uniquely provided by aspirin: antiplatelet + antiinflammatory + cancer chemoprevention/detection.
Part 4: Reconciling the Bleeding Risk Debate
4.1 The Bleeding Controversy
Recent meta-analyses report aspirin increases bleeding risk in primary prevention:
58% increased major GI bleeding (OR 1.58, 95% CI 1.29-1.95)[acpjournals]
27% increased hemorrhagic stroke (OR 1.27, 95% CI 0.96-1.68)[acpjournals]
1.39 excess major bleeding events per 1,000 person-years[acpjournals]
In primary prevention, bleeding risk is "unopposed" while cardiovascular benefit is modest.[pubmed.ncbi.nlm.nih]
4.2 Reinterpretation: Bleeding as Early Detection Signal
The Danish study suggests bleeding on aspirin may not be purely harmful:
4.3 Risk Stratification Approach
Current guidelines use bleeding risk stratification to balance benefits:
Aspirin appropriate when:
Secondary prevention (established ASCVD)
Primary prevention + 40-70 years + high ASCVD risk + no bleeding risk
Willing to take daily aspirin + no increased bleeding risk[acc]
Aspirin inappropriate when:
Age >70 years
Increased bleeding risk (any age)
Low ASCVD risk + primary prevention[pmc.ncbi.nlm.nih]
This approach maintains aspirin's role while acknowledging bleeding risk.
Part 5: Responding to ACC 2026 Guidance Criticism of Aspirin
5.1 What the ACC Statement Actually Says
The ACC Antiplatelet Guidance (2026) synthesizes major guidelines and maintains:
Aspirin remains standard for chronic coronary syndromes/remote revascularization
12-month DAPT default post-ACS aligns with ACC/AHA + ESC
Bleeding risk algorithms stratify patients for de-escalation to SAPT within weeks-months
Shorter DAPT + ticagrelor monotherapy increasingly supported
The statement explicitly acknowledges harmony between American and European guidelines on aspirin for medically treated chronic coronary syndromes.
5.2 What the ACC Statement Doesn't Address
The ACC guidance focuses on antiplatelet efficacy and bleeding risk but overlooks:
Antiinflammatory mechanism: No discussion of aspirin's COX-2 acetylation or lipoxin generation[pmc.ncbi.nlm.nih]
Metabolic-inflammatory disease targeting: No recognition that aspirin addresses atherosclerosis pathophysiology beyond thrombosis
Cancer detection benefit: Bleeding discussed purely as harm, not as early cancer warning
Chemoprotective effects: Cancer prevention not considered in benefit-risk assessment
5.3 Why This Matters for Clinical Decision-Making
The ACC statement's narrow focus on antiplatelet effects and bleeding risk may underestimate aspirin's true benefit:
Traditional benefit: Antiplatelet effect prevents thrombosis
Hidden benefit: Antiinflammatory effect targets disease progression
Unexpected benefit: Bleeding unmasks silent cancer → earlier diagnosis
This creates a systematic bias favoring P2Y12 inhibitors in de-escalation strategies when their actual superiority remains unproven.[acc]
Part 6: The Three-Pronged Advantage of Aspirin
6.1 Summary of Mechanisms
6.2 Why P2Y12 Inhibitors Cannot Replace Aspirin
Despite encouraging de-escalation results, P2Y12 inhibitors lack critical advantages:
No antiinflammatory effect: Do not acetylate COX-2 or generate lipoxins[pubmed.ncbi.nlm.nih]
No cancer detection benefit: Bleeding not associated with early cancer detection[medicalxpress]
Unproven superiority: No regulatory claim for superiority vs. aspirin[acc]
Underutilization of aspirin: Global secondary prevention aspirin use remains insufficient[acc]
The 2026 ACC statement acknowledges ESC preference for prasugrel over ticagrelor post-PCI but notes no analogous ACC/AHA recommendation, indicating guideline divergence rather than consensus.
Conclusions and Recommendations
7.1 Aspirin Maintains First-Choice Position
Three mechanisms support aspirin as antiplatelet of first choice in ASCVD:
Dual pharmacodynamic action: Antiplatelet + antiinflammatory targeting atherosclerosis as metabolic-inflammatory disease
Guideline-supported efficacy: Current ACC/AHA/ESC guidelines maintain aspirin for secondary prevention and selective primary prevention
Cancer screening benefit: Aspirin-triggered bleeding unmasks silent malignancies, providing early detection and improved outcomes
7.2 Clinical Recommendations
For Secondary Prevention:
Maintain aspirin as cornerstone therapy (75-100 mg/day)
Do not substitute P2Y12 inhibitors without compelling evidence
Address underutilization in low-income countries
For Primary Prevention:
Use in high-risk patients (40-70 years, ≥10% 10-year CVD risk, no bleeding risk)
Avoid in >70 years or increased bleeding risk
Consider cancer screening benefit in risk-benefit discussion
For Acute Coronary Syndromes:
Follow 12-month DAPT default per ACC/AHA guidelines
Consider de-escalation to SAPT when bleeding risk stratified
Recognize aspirin's antiinflammatory benefit during ACS
7.3 Research Directions
Future studies should:
Test antiinflammatory-based aspirin strategies vs. P2Y12 monotherapy
Quantify cancer detection benefit in cardiovascular trials
Reassess bleeding risk interpretation (detection signal vs. harm)
Develop personalized aspirin dosing based on inflammatory markers
7.4 Critical Call to Specialists
The style and motive of this article is to attract specialists to more carefully estimate modern attacks on aspirin.Recent scientific media criticism and emerging P2Y12 inhibitors have created a narrative questioning aspirin's role, particularly in primary prevention. However, this formation may be premature and incomplete. In reality, aspirin can occur as the better choice in both primary and secondary prevention applications due to its unique three-pronged advantage: dual antiplatelet+antiinflammatory pharmacodynamic mechanism, guideline-supported efficacy, and unexpected cancer screening benefit.
Specialists should critically reassess:
Are modern attacks on aspirin justified by complete evidence? Recent criticism focuses on bleeding risk but overlooks antiinflammatory benefits and cancer detection role
Is P2Y12 inhibitor superiority proven? No regulatory claim exists for superiority vs. aspirin; current guidelines maintain aspirin's position
Are we underestimating aspirin's true benefit? Bleeding may represent early cancer detection rather than purely harmful event
What is the pathophysiological rationale? Atherosclerosis is metabolic-inflammatory disease—does aspirin's dual mechanism better address this than P2Y12 inhibitors alone?
The verdict may differ when all mechanisms are considered. Aspirin's primacy in ASCVD management deserves continued support, not dismissal based on incomplete benefit-risk assessment.
7.5 Final Statement
Despite recent criticism, aspirin remains the antiplatelet of first choice in atherosclerotic cardiovascular disease. Its dual antiplatelet+antiinflammatory mechanism uniquely addresses atherosclerosis as a metabolic-inflammatory disease, current guidelines maintain its position in secondary and selective primary prevention, and its unexpected cancer screening role provides additional health benefits. P2Y12 inhibitors show promise in de-escalation strategies but lack proven superiority and cannot replicate aspirin's three-pronged advantage.
Aspirin's primacy in ASCVD management is justified by pathophysiology, evidence, and guidelines—and may be strengthened by recognition of its cancer screening role. Specialists should approach modern attacks on aspirin with critical skepticism and demand complete evidence before abandoning this cornerstone therapy.
References
The article synthesizes evidence from:
2026 ACC Antiplatelet Guidance[medscape]
Current ACC/AHA/ESC guidelines[pubmed.ncbi.nlm.nih]
Danish bladder cancer study 2026[medicalxpress]
Aspirin antiinflammatory mechanisms[pubmed.ncbi.nlm.nih]
Cancer prevention meta-analyses[pmc.ncbi.nlm.nih]
Bleeding risk systematic reviews[pubmed.ncbi.nlm.nih]
Comments